Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Screens02:46

Genetic Screens

4.6K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
4.6K
Preventive Healthcare Services01:30

Preventive Healthcare Services

2.3K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.3K
Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

1.9K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the 4Kscore in EPIC: Letter.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Transcriptome-wide association studies implicate RCC1 and PHACTR4 in prostate cancer survival.

European journal of human genetics : EJHG·2026
Same author

Radical Prostatectomy in Low-volume Metastatic Prostate Cancer? The Need for New Evidence.

European urology·2026
Same author

An evaluation of artificial intelligence assisted prostate biopsy reporting in the Articulate Pro study.

NPJ digital medicine·2026
Same author

Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.

BJU international·2026
Same author

Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model.

European urology focus·2026
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

831

Emerging PSA-based tests to improve screening.

Richard J Bryant1, Hans Lilja2

  • 1Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Headley Way, Headington, Oxford OX3 9DU, UK.

The Urologic Clinics of North America
|April 15, 2014
PubMed
Summary
This summary is machine-generated.

Advances in prostate cancer screening using prostate-specific antigen (PSA) and kallikrein markers show survival benefits but carry risks. A more accurate screening test is needed to identify aggressive cancers and reduce unnecessary treatments.

Keywords:
DetectionKallikreinsPSAProstate cancerScreening

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

12.6K

Related Experiment Videos

Last Updated: May 1, 2026

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection
10:02

Standardized SDS-PAGE Workflow for Personalized Protein Corona Profiling in Early Cancer Detection

Published on: December 19, 2025

831
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

12.6K

Area of Science:

  • Urology
  • Oncology
  • Biomarkers

Background:

  • Prostate cancer screening, primarily via prostate-specific antigen (PSA) testing, has evolved with new derivatives and human kallikrein markers.
  • Current screening methods identify many indolent prostate cancers that do not require treatment, leading to overtreatment and associated side effects.
  • While screening offers a survival benefit, the high numbers needed to screen and treat underscore the need for improved diagnostic accuracy.

Purpose of the Study:

  • To update on the latest advancements in prostate cancer screening technologies.
  • To evaluate the performance characteristics of new biomarkers for early prostate cancer detection.
  • To address the challenge of distinguishing indolent from aggressive prostate cancer to optimize treatment decisions.

Main Methods:

  • Review of recent literature on prostate-specific antigen (PSA) derivatives and human kallikrein markers in prostate cancer screening.
  • Analysis of the efficacy and limitations of current screening protocols.
  • Assessment of the diagnostic performance required for an ideal screening test.

Main Results:

  • Evidence supports a survival benefit from prostate cancer screening, but the number needed to screen and treat remains high.
  • Current markers can lead to the diagnosis of indolent disease, increasing the risk of overtreatment and side effects.
  • The need for improved screening tests with better performance characteristics is evident.

Conclusions:

  • Further development of prostate cancer screening tools is crucial to enhance early detection of life-threatening disease.
  • Improved screening accuracy can help reduce unnecessary biopsies and the overtreatment of indolent prostate cancers.
  • The goal is to identify cancers with curative intent while minimizing harm from non-life-threatening disease and its treatment.